CD14 expression and Kupffer cell dysfunction in non-alcoholic steatohepatitis: Superparamagnetic iron oxide-magnetic resonance image and pathologic correlation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 4, 2012, Pages 789-796

  Tonan, Tatsuyuki ^a   Fujimoto, Kiminori ^a,b   Qayyum, Aliya ^e   Morita, Yasuyo ^c   Nakashima, Osamu ^b   Ono, Noriyuki ^d   Kawahara, Akihiko ^a   Kage, Masayoshi ^a   Hayabuchi, Naofumi ^a   Ueno, Takato ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY HOSPITAL   (Japan)

^c Nagata Hospital   (Japan)

^d Chikugo City Hospital   (Japan)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fibrosis stage; Kupffer cell; Magnetic resonance imaging; Necroinflammatory grade; Non alcoholic fatty liver disease; Non alcoholic steatohepatitis; Superparamagnetic iron oxide

Indexed keywords

CD14 ANTIGEN; SUPERPARAMAGNETIC IRON OXIDE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; DISEASE SEVERITY; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KUPFFER CELL; LIVER FIBROSIS; LIVER SURGERY; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84858824628     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07057.x     Document Type: Article

References (34)

1. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
2. Ludwig J, Viggiano TR, McGill DB etal. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo. Clin. Proc. 1980; 55: 434-8.
3. Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J. Hepatol. 2009; 51: 212-23.
4. Diehl AM. Nonalcoholic steatosis and steatohepatitis IV. Nonalcoholic fatty liver disease abnormalities in macrophage function and cytokines. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 282: G1-5.
5. Day CP. Genes or environment to determine alcoholic liver disease and non-alcoholic fatty liver disease. Liver Int. 2006; 26: 1021-8.
6. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-5.
7. Tonan T, Fujimoto K, Azuma S etal. Evaluation of small (< or=2cm) dysplastic nodules and well-differentiated hepatocellular carcinomas with ferucarbotran-enhanced MRI in a 1.0-T MRI unit: utility of T2-weighted gradient echo sequences with an intermediate-echo time. Eur. J. Radiol. 2007; 64: 133-9.
8. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.
9. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-74.
10. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
11. Fujimoto K, Tonan T, Azuma S etal. Evaluation of the mean and entropy of apparent diffusion coefficient values in chronic hepatitis C: correlation with pathologic fibrosis stage and inflammatory activity grade. Radiology 2011; 258: 739-48.
12. Gandon Y, Olivi'e D, Guyader D etal. Non-invasive assessment of hepatic iron stores by MRI. Lancet 2004; 363: 357-62.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
14. Lefkowitch JH, Haythe JH, Regent N. Kupffer cell aggregation and perivenular distribution in steatohepatitis. Mod. Pathol. 2002; 15: 699-704.
15. Ferrero E, Jiao D, Tsuberi BZ etal. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc. Natl. Acad. Sci. U. S. A. 1993; 90: 2380-4.
16. Soler-Rodriguez AM, Zhang H, Lichensten H etal. Neutrophil activation by bacterial lipoprotein versus lipopolysaccharide: differential requirements for serum and CD14. J. Immunol. 2000; 164: 2674-83.
17. Giambartolomei GH, Dennis VA, Lasater BL, Philipp MT. Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14. Infect. Immun. 1999; 67: 140-7.
18. Su GL, Goyert SM, Fan MH etal. Activation of human and mouse Kupffer cells by lipopolysaccharide is mediated by CD14. Am. J. Physiol. 2002; 283: G640-5.
19. Martin TR, Mongovin SM, Tobias PS etal. The CD14 differentiation antigen mediates the development of endotoxin responsiveness during differentiation of mononuclear phagocytes. J. Leukoc. Biol. 1994; 56: 1-9.
20. Su GL. Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am. J. Physiol. 2002; 283: G256-65.
21. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001; 34: 101-8.
22. Moore KJ, Andersson LP, Infalls RR etal. Divergent response to LPS and bacteria in CD14 deficient murine macrophages. J. Immunol. 2000; 165: 4272-80.
23. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 2557-62.
24. Ruiz AG, Casafont F, Crespo J etal. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 2007; 17: 1374-80.
25. Bhunchet E, Eishi Y, Wake K. Contribution of immune response to the hepatic fibrosis induced by porcine serum. Hepatology 1996; 23: 811-17.
26. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J. Hepatol. 2003; 38: 681-7.
27. Tomita K, Tanimoto A, Irie R etal. Evaluating the severity of nonalcoholic steatohepatitis with superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 2008; 28: 1444-50.
28. Tsujimoto T, Kawaratani H, Kitazawa T etal. Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model. World J. Gastroenterol. 2008; 14: 6036-43.
29. Asanuma T, Ono M, Kubota K etal. Super paramagnetic iron oxide MRI shows defective Kupffer cell uptake function in non-alcoholic fatty liver disease. Gut 2010; 59: 258-66.
30. Kawaratani H, Tsujimoto T, Kitazawa T etal. Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J. Gastroenterol. 2008; 14: 6655-61.
31. Chen J, Talwalkar JA, Yin M, Glaser KJ, Sanderson SO, Ehman RL. Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology 2011; 259: 749-56.
32. Leicester KL, Olynyk JK, Brunt EM, Britton RS, Bacon BR. Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis. Liver Int. 2006; 26: 559-65.
33. Leicester KL, Olynyk JK, Brunt EM, Britton RS, Bacon BR. CD14-positive hepatic monocytes/macrophages increase in hereditary hemochromatosis. Liver Int. 2004; 24: 446-51.
34. Thuy S, Ladurner R, Volynets V etal. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J. Nutr. 2008; 138: 1452-5.